Research report
A research report is the sourced material a domain
dossier is synthesized from — generated on a plan and a cadence, one topic per file.
A report carries no confidence tags. Its bracketed markers say who might have
an incentive to shade a line; none of them says anyone checked it. To reach a score, a line has
to be drafted onto a candidate as unverified and pass the Verifier or the
Corroborator, like everything else.
Section technology · Version 2026-09-01 · Cadence annual · Evidence class 2 published · Sources 11 · Supersedes none
Domain: canine-equine-distal-limb-wounds · Scope: public primary sources via connectors, WebSearch and WebFetch. Excludes CPT descriptors (AMA-licensed), veterinary datasets (no US federal dataset exists), fda.gov guidance documents, anything behind an unset PATENTSVIEW_API_KEY, and jurisdictions other than US and EU.
Sourcing: eleven peer-reviewed veterinary studies, each a single small case series, pilot experiment, or randomized trial; no two independent sources report the same quantitative finding, so every measured result here is single-source
The domain dossier's own technology section (§7) already tracks the negative-pressure wound therapy (NPWT) clearance trajectory this candidate is positioned against; this report looks past that one device category at what else moved in the surrounding literature over the last decade. What moved is not a single new incumbent but a proliferation of small, single-institution trials of regenerative, topical, and energy-based adjuncts — platelet-rich plasma, mesenchymal stromal cells, amnion allograft, an amorphous silicate dressing, ozone bagging, photobiomodulation, hyperbaric oxygen, and early tissue-engineered canine skin substitutes — none of which has yet produced a trial large enough to move a guideline. A 2022 scoping review of the equine exuberant-granulation-tissue (EGT) literature, having screened 35 controlled clinical trials across university hospitals, concluded there remains "a strong need for evidence-based recommendations" [4] — and the mixed direction of the individual studies below (one positive comparator result, two negative ones, in the same anatomical population) is consistent with that conclusion rather than contradicting it.
_Baseline (v1). No prior version; this establishes the starting point for future diffs._
Three biologic modalities were tested against the equine distal-limb wound model in the window searched, and they do not agree with each other. In a surgically-created wound model in 8 horses (four 4 cm² wounds each), autologous platelet-rich plasma (PRP) applied as a gel reduced healing time by 15 days relative to a saline-injected control group, the largest effect of the three treatment arms tested [1] [single-source]. By contrast, a randomized, controlled trial of intravenous allogeneic cord-blood-derived mesenchymal stromal cells (MSC) in 12 horses with induced limb wounds found the treatment "did not accelerate wound closure or improve histologic healing," although it decreased wound size and most measured cytokine levels [6] [single-source]. Local injection of an equine-origin liquid amnion allograft in a third experimental model (8 horses, paired wounds) likewise found no difference from saline control in wound area over time or time to 95% size reduction, concluding a single treatment "did not accelerate distal limb wound healing in horses" [3] [single-source]. Read together, these three sources report the same outcome measure (time to closure or wound area) on the same anatomical site and disagree on direction — one shows benefit, two do not — which is itself the state of the evidence, not a gap in this report's search.
Two topical approaches specific to preventing or resolving exuberant granulation tissue (EGT) on the equine distal limb appear in case-series form. An amorphous silicate dressing, evaluated in 11 client-owned horses with naturally occurring distal-limb wounds referred from practices across the US, was associated with no cases requiring granulation-bed debridement and resolution times of 14–126 days (median 49); the study had no comparator arm [2] [single-source]. Separately, an 8-horse case series of chronic distal-limb wounds "refractory to conventional management" treated exclusively with topical ozone via bagging (50 μg/mL, 30 minutes every 48 hours) achieved complete closure in all 8 cases within 27–91 days without systemic medication; the authors describe the method in their own words as "simple, cost-effective, and well-tolerated," and call for controlled trials against conventional therapy, which none has yet run [5] [single-source]. Both are candidate adjuncts, not established practice — the scoping review above [4] is the frame for reading both this way.
An in vitro comparison of four equine wound pathogens (including a clinical Streptococcus zooepidemicus isolate) against ten antimicrobial dressings and topicals found that the minimum inhibitory and bactericidal concentrations of medical-grade manuka honey, local honey, and food-grade honey were comparable to sterile gauze and sugar, while polyhexamethylene biguanide (PHMB) gauze and foam required a higher dilution than most other agents to remain effective; the authors flag that in vitro susceptibility has not been tested in vivo for this species-specific comparison [8] [single-source].
A randomized controlled trial of 21 client-owned dogs with chronic wounds (anatomical site not restricted to the distal limb) found photobiomodulation therapy (PBMT) produced significantly greater wound-area reduction than saline-only control by day 15 for both an 830 nm protocol (56.98% ± 24.82% reduction) and a simultaneous multi-wavelength protocol (61.81% ± 27.18%), against 42.39% ± 20.58% for control (p<0.05) [7] [single-source]. In a separate, larger randomized, blinded trial of 36 dogs with Crotalinae (pit viper) envenomation wounds, hyperbaric oxygen therapy (HBOT, 2 atmospheres absolute) produced no significant difference in wound swelling, severity score, or pain score relative to a sham-pressure control, with the authors noting the study "might be underpowered to detect a significant treatment effect" [11] [single-source]. Neither trial is scoped to the distal limb specifically, and both are named here as the state of canine wound-technology evidence generally rather than as this domain's exact population.
Two early-phase efforts to build a canine skin substitute appear in the decade searched. A bioengineered autologous full-thickness skin construct, grown from punch-biopsy keratinocytes and fibroblasts on a fibrin matrix, was validated in xenograft mice and then applied clinically to 2 dogs with large deep wounds, both of which achieved "successful grafting" and "permanent epithelialisation" in this proof-of-concept report [9] [single-source]. A commercially-named acellular collagen biomembrane (Eva Scientific Ltd, São Paulo, Brazil) reached a Phase I veterinary interim report of a planned 15-patient (dog and cat) trial; of 3 enrolled patients, 2 completed treatment and both healed fully with no adverse effects, at a healing rate the authors describe as "maxing out at approximately 1 cm²/day" [10] [single-source]. Neither product's regulatory status (FDA device classification, if any, or unregulated biologic) was established in this pass.
[1] Evaluation of Three Methods of Platelet-Rich Plasma for Treatment of Equine Distal Limb Skin Wounds — Journal of Equine Veterinary Science (published 2019, month not given in the PubMed record; accessed 2026-09-01). PMID 30929771 — https://pubmed.ncbi.nlm.nih.gov/30929771/ [peer-reviewed] [2] Amorphous silicate technology produces good results in equine distal limb wound healing — Journal of the American Veterinary Medical Association (published 2023-06-01; accessed 2026-09-01). PMID 37085146 — https://pubmed.ncbi.nlm.nih.gov/37085146/ [peer-reviewed] [3] Healing time of experimentally induced distal limb wounds in horses is not reduced by local injection of equine-origin liquid amnion allograft — American Journal of Veterinary Research (published 2022-07-13; accessed 2026-09-01). PMID 35895786 — https://pubmed.ncbi.nlm.nih.gov/35895786/ [peer-reviewed] [4] The granulation (t)issue: A narrative and scoping review of basic and clinical research of the equine distal limb exuberant wound healing disorder — The Veterinary Journal (published 2022-02, day not given in the PubMed record; accessed 2026-09-01). PMID 35093532 — https://pubmed.ncbi.nlm.nih.gov/35093532/ [peer-reviewed] [5] Efficacy of Ozone Bagging Therapy in Equine Chronic Distal Limb Wounds: Clinical Evaluation of Eight Cases — Veterinary Sciences (published 2025-12-23; accessed 2026-09-01). PMID 41600672 — https://pubmed.ncbi.nlm.nih.gov/41600672/ [peer-reviewed] [6] Macroscopic, Histologic, and Immunomodulatory Response of Limb Wounds Following Intravenous Allogeneic Cord Blood-Derived Multipotent Mesenchymal Stromal Cell Therapy in Horses — Cells (published 2021, month not given in the PubMed record; accessed 2026-09-01). PMID 34831196 — https://pubmed.ncbi.nlm.nih.gov/34831196/ [peer-reviewed] [7] Assessment of wound area reduction on chronic wounds in dogs with photobiomodulation therapy: A randomized controlled clinical trial — Veterinary World (published 2021-08, day not given in the PubMed record; accessed 2026-09-01). PMID 34566346 — https://pubmed.ncbi.nlm.nih.gov/34566346/ [peer-reviewed] [8] Comparison of In Vitro Bacterial Susceptibility to Common and Novel Equine Wound Care Dressings — Animals (published 2024-03-01; accessed 2026-09-01). PMID 38473161 — https://pubmed.ncbi.nlm.nih.gov/38473161/ [peer-reviewed] [9] Proof of concept of a new autologous skin substitute for the treatment of deep wounds in dogs — The Veterinary Journal (published 2017-12, day not given in the PubMed record; accessed 2026-09-01). PMID 29208214 — https://pubmed.ncbi.nlm.nih.gov/29208214/ [peer-reviewed] [10] Regenerative collagen biomembrane: Interim results of a Phase I veterinary clinical trial for skin repair — F1000Research (published 2018, month not given in the PubMed record; accessed 2026-09-01). PMID 30687496 — https://pubmed.ncbi.nlm.nih.gov/30687496/ [peer-reviewed] [11] The effects of hyperbaric oxygen therapy on snake-bite-associated wounds in dogs — Journal of Veterinary Emergency and Critical Care (published 2024, month not given in the PubMed record; accessed 2026-09-01). PMID 38761038 — https://pubmed.ncbi.nlm.nih.gov/38761038/ [peer-reviewed]
Well established: that the equine EGT literature lacks an evidence-based treatment recommendation rests on two independent, non-affiliated things agreeing — the 2022 scoping review's own stated conclusion after screening 35 controlled trials [4], and the fact that the three biologic-adjunct studies retrieved here, run at different institutions, disagree with each other on the direction of effect for the same outcome measure on the same anatomical site [1][3][6]. Nothing else in this report reaches two-source agreement.
Thin: every quantitative finding in §3 rests on exactly one study and carries [single-source] — sample sizes range from 2 completed patients [10] to 36 dogs [11], none is a multi-centre trial, and none has a distal-limb-specific comparator arm larger than 12 animals per side. The photobiomodulation [7] and hyperbaric oxygen [11] trials are the state of canine wound-care evidence generally, not confirmed as distal-limb-specific populations — stated explicitly in §3 rather than folded into this domain's population silently.
Rescoped from class 3: none. This report answers a class-2 question — what changed in the published record — and did not encounter an unanswerable stakeholder-future question to rescope.
Out of scope: CPT descriptors (AMA-licensed); veterinary datasets requiring a license; fda.gov guidance documents (intermittent bot mitigation); a patent-landscape check on any of the technologies named here, blocked by the same unset PATENTSVIEW_API_KEY the domain dossier's own §7 already names as a gap; any jurisdiction outside the US and EU.
Not searched vs. not found:
clearances/classification connector query was
run against these product categories this pass. Also not searched: list price or per-treatment
cost for any modality named above (the ozone study's own "cost-effective" characterization [5]
is the authors' unquantified claim, not an independently sourced price); 3D-printed
splinting/casting technology for the distal limb; cold atmospheric plasma treatment of
veterinary wounds; wearable or telehealth monitoring adjuncts for either species.
[inference] The framing that none of these technologies has displaced conventional bandaging or NPWT as this domain's reference standard is the writer's own synthesis, not a stated finding of any source above — it follows from the fact that the domain dossier's own reference-products section (§5), built the same week, still treats bandaging and NPWT as the incumbents and none of the technologies named here appear in it. [inference] The Eva Scientific biomembrane trial's funding source is not stated in the retrieved abstract; naming the manufacturer in the citation is not the same as confirming sponsorship, and this report does not resolve that ambiguity either way — it is disclosed rather than assumed.
Propositions a checker could attempt. This report does not append them — /research drafts them onto a candidate with engine/scripts/append_research_claims.py, which constructs the unverified tag itself.
| Proposition | Evidence class | Resolvable identifier | Dossier section |
|---|---|---|---|
| Autologous platelet-rich plasma gel reduced healing time by 15 days compared with saline-injected control wounds in an 8-horse experimentally induced distal-limb wound model | 2 published | PMID 30929771 | 4 |
| Intravenous allogeneic cord-blood-derived mesenchymal stromal cell therapy did not accelerate wound closure or improve histologic healing in a randomized controlled trial of 12 horses with induced limb wounds | 2 published | PMID 34831196 | 4 |
| Local injection of equine-origin liquid amnion allograft did not reduce healing time of experimentally induced distal-limb wounds compared with saline control in 8 horses | 2 published | PMID 35895786 | 4 |
| An amorphous silicate topical dressing was associated with no cases requiring granulation-bed debridement in a case series of 11 horses with naturally occurring distal-limb wounds | 2 published | PMID 37085146 | 7 |
| Ozone bagging therapy achieved full wound closure in all 8 treated horses with chronic distal-limb wounds within 27 to 91 days, with no systemic medication | 2 published | PMID 41600672 | 7 |
| Photobiomodulation therapy produced significantly greater wound-area reduction than saline-only control by day 15 in a randomized controlled trial of 21 dogs with chronic wounds | 2 published | PMID 34566346 | 4 |
| Hyperbaric oxygen therapy did not significantly reduce wound swelling, severity, or pain scores compared with sham-pressure control in a randomized controlled trial of 36 dogs with snakebite-associated wounds | 2 published | PMID 38761038 | 4 |